Vivos Therapeutics Signs $12M M&A Deal with SOD Sciences, Inc.
Vivos Therapeutics completed the acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test. The transaction was valued at $12 million, paid via the issuance of 12,000 shares of Series C Convertible Preferred Stock, and is expected to add over $10 million to Vivos' stockholders' equity.
Value
$12M
Counterparty
SOD Sciences, Inc.
“Today Vivos became more than a healthcare company just treating sleep apnea. We expect this transaction to add more than $10 million to our stockholders’ equity, and we now own half of a test designed to identify patients whose sleep apnea may be contributing to chronic disease.”
R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos
Vivos Therapeutics Signs $12M M&A Deal with SOD Sciences, Inc.
Vivos Therapeutics entered into a definitive agreement to acquire an 11% equity stake in SOD Sciences and a 50% co-ownership interest in a proprietary pseudohypoxia early-warning test. The transaction is valued at $12 million, paid via the issuance of 12,000 shares of newly created Series C Convertible Preferred Stock, and is intended to bolster stockholders' equity for Nasdaq compliance.